{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-030113","form_type":"8-K","ticker":"PPCB","cik":"0001517681","company_name":"Propanc Biopharma, Inc.","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.950003+00:00","generated_at":"2026-06-22T18:05:09.037205+00:00","sec_items":["5.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Propanc Biopharma enters amended employment agreement with CEO James Nathanielsz","bullets":["New base salary of $600,000 AUD per annum, plus salary sacrifice for tuition up to $200,000 AUD.","Annual discretionary bonus reduced to up to 100% of base salary (from 200% previously).","Term of 3 years from July 1, 2022, with automatic yearly renewal unless terminated.","Severance: one year's base salary upon termination without cause or company non-renewal; only accrued amounts if executive non-renewal.","Includes one-year non-compete and indemnification provisions."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-030113","json":"https://secwatch.observer/filing/0001493152-22-030113.json","markdown":"https://secwatch.observer/filing/0001493152-22-030113.md","text":"https://secwatch.observer/filing/0001493152-22-030113.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1517681/000149315222030113/0001493152-22-030113-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1517681/000149315222030113/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T18:05:09.037205+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}